Intel stock extends gains after report of possible U.S. government stake
BOTHELL, WA—Sarah Aebersold, the Chief Human Resources Officer of BioLife Solutions Inc. (NASDAQ:BLFS), recently sold a total of 8,415 shares of the company’s common stock. The transactions, carried out on March 11 and March 12, were made under a prearranged trading plan. The sale comes as the company’s stock has shown significant momentum, with a 49% return over the past year, according to InvestingPro data.
On March 11, Aebersold sold 1,091 shares at a price of $25.00 each, totaling $27,275. The following day, she sold an additional 7,324 shares at $26.34 per share, amounting to $192,914. These sales were executed under Rule 10b5-1 trading plans, which allow insiders to set up a predetermined schedule for selling company stock to avoid concerns about insider trading. The transactions occurred as BioLife Solutions maintains a strong financial health score and operates with a moderate debt level, with current assets more than four times its short-term obligations.
Following these transactions, Aebersold retains ownership of 51,492 shares of BioLife Solutions. The company, headquartered in Bothell, Washington, specializes in the development of biopreservation tools for cells, tissues, and organs. With a market capitalization of $1.17 billion and revenue growth of 8.4% in the last twelve months, BioLife Solutions continues to expand its presence in the biopreservation market.
In other recent news, BioLife Solutions reported strong financial results for the fourth quarter and the full year of 2024, with a total revenue of $22.7 million for the quarter, exceeding analyst estimates. The company posted a net loss of $2.0 million, or ($0.04) per share, which was smaller than projected. For the entire year, BioLife Solutions achieved total revenue of $82.3 million, excluding revenue from discontinued operations. Analysts from H.C. Wainwright and Benchmark maintained a "Buy" rating on the stock, with both firms setting a price target of $30.00, reflecting confidence in the company’s future performance. BioLife’s Cell Processing segment experienced a significant revenue increase, contributing to the overall positive financial outcomes. The company has also completed the sale of a non-core product line to enhance its gross margin and adjusted EBITDA margin. Looking ahead to 2025, BioLife Solutions anticipates total revenue growth between 16% and 20%, with expectations for Cell Processing revenue to rise by 18-21%. The company’s biopreservation media is currently integrated into 17 approved therapies, with potential for further approvals in the coming year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.